» Articles » PMID: 12513005

Anti-tumour Necrosis Factor Therapy for Severe Inflammatory Arthritis: Two Years of Experience in Northern Ireland

Overview
Journal Ulster Med J
Specialty General Medicine
Date 2003 Jan 7
PMID 12513005
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Etanercept and infliximab are novel biological agents targeted against tumour necrosis factor alpha (TNFalpha), a key cytokine in the pathogenesis of rheumatoid arthritis (RA). We report the results of their use over a two year period in 94 patients with severe inflammatory arthritis. Eighty-eight adults with active inflammatory arthritis (82 with RA), unresponsive to all conventional treatment, received biological therapy in one of five specialist centres in Northern Ireland. 69 adult patients (78%) had a good response to treatment, four a partial response, and seven no response. The results of treatment could not be assessed in eight patients because they had only recently commenced therapy. Four patients had a mild allergic reaction to treatment but one patient developed fulminant lung fibrosis which may have been due to drug therapy and eventually proved fatal. There were four cases of major infection requiring hospitalisation. Two patients responded to treatment, but one succumbed to bacterial pneumonia, and another to bacterial meningitis. Six children with juvenile idiopathic arthritis (JIA) received etanercept. Four achieved a good response, one a partial response, and one no response to treatment. This study shows that the impressive response to anti-TNF therapies extends beyond the realm of clinical trials to everyday clinical practice. These agents represent a major advance in the treatment of severe inflammatory arthritis but they should be used with caution, particularly in the elderly and in patients who are predisposed to infection.

Citing Articles

Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats.

Altintas N, Erboga M, Aktas C, Bilir B, Aydin M, Sengul A Inflammation. 2015; 39(1):65-78.

PMID: 26253295 DOI: 10.1007/s10753-015-0224-z.


Rational design of antirheumatic prodrugs specific for sites of inflammation.

Onuoha S, Ferrari M, Sblattero D, Pitzalis C Arthritis Rheumatol. 2015; 67(10):2661-72.

PMID: 26097196 PMC: 4832285. DOI: 10.1002/art.39232.


Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3.

Armstrong L, Godinho S, Uppington K, Whittington H, Millar A Clin Exp Immunol. 2009; 156(2):336-43.

PMID: 19292764 PMC: 2759483. DOI: 10.1111/j.1365-2249.2009.03906.x.


Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report.

Booker M, Flint J, Saravana S Cases J. 2008; 1(1):364.

PMID: 19046446 PMC: 2612655. DOI: 10.1186/1757-1626-1-364.


[Vaccination in adult rheumatology].

Rubbert-Roth A Z Rheumatol. 2007; 66(2):102-4, 106-10.

PMID: 17294061 DOI: 10.1007/s00393-007-0144-x.


References
1.
Mitchell D, Spitz P, Young D, Bloch D, McShane D, Fries J . Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 1986; 29(6):706-14. DOI: 10.1002/art.1780290602. View

2.
Husby G, Williams Jr R . Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun. 1988; 1(4):363-71. DOI: 10.1016/0896-8411(88)90006-6. View

3.
Hulsmans H, Jacobs J, van der Heijde D, van Albada-Kuipers G, Schenk Y, Bijlsma J . The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum. 2000; 43(9):1927-40. DOI: 10.1002/1529-0131(200009)43:9<1927::AID-ANR3>3.0.CO;2-B. View

4.
Garrett S, Jenkinson T, Kennedy L, Whitelock H, Gaisford P, Calin A . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21(12):2286-91. View

5.
Fries J, Williams C, Morfeld D, Singh G, Sibley J . Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 1996; 39(4):616-22. DOI: 10.1002/art.1780390412. View